About Neornat
CEO Message
Company Identity
NEORNAT Inc. is a company that researches and develops first-in-class anticancer drugs that target RNA regulators.


- The New RNA Therapeutics Company
- First-in-Class Target Therapeutics
History
2023
-
01
Published an article on Experimental & Molecular Medicine (IF: 12.153) : ADAR1-dependent miR-3144-3p editing simultaneously induces MSI2 expression and suppresses SLC38A4 expression in liver cancer
2022
-
11
Selected as Korea Angel Investment TIPS
-
09
Established R&D Center (located in Banpo-dong, Seocho-gu)
-
06
Steintech Bio Season 1, Final Round Top 5 Selection and Best Company Selection
Published an article on Experimental & Molecular Medicine (IF: 12.153) : hnRNPC induces isoform shifts in miR-21-5p leading to cancer development -
03
Completed pre-round Series A investment
2021
-
12
Signed out of license out with KPS Co., Ltd. for liver cancer diagnosis/analysis technology
Catholic University Industry-University Cooperation Foundation- NEORNAT Inc. transfers 3 technologies for new drug development -
08
Published in Oncogene (IF:9.867) paper
-
07
Selected as Korea Angel Investment TIPS
-
04
Selected as a 3-year project for the disease-centered translational research project
-
01
Shinhan Capital Investment Attraction
2020
-
11
Catholic University Industry-University Cooperation Foundation - Completed technology transfer for 4 cases of NEORNAT Inc.
-
10
Selected as K-BIC STAR (New drug development start-up company, Korea Health Industry Promotion Agency)
-
09
Completed attracting angel investment
Established NEORNAT Inc.
People



CEO Suk Woo Nam
-
Professor, Dept of Pathology, College of Medicine,
The Catholic Univ. of Korea -
Director, Functional RNomics Research Center (FRRC),
The Catholic Univ. of Korea - Associate Editor, Biomolecules
- Advisory Editorial Board, Molecular & Cellular Toxicology
- Advisory Editorial Board, Archives of Pharmacal Research
- Member, American Associate for Cancer Research
- Member, National Academy of Medicine of Korea
- Member, The Korean Cancer Association
- Member, The Pharmaceutical Society of Korea
- Member, Korea Genome Organization

CSO&CDD Ki Ho Moon
-
30 years of pharmaceutical industry experience
(New drug research, Clinical development, Marketing) - Graduated from the Department of Pharmacy and Graduate School of Pharmacy, Sungkyunkwan University

Leader Hee Doo Yang
- Lab of Cancer RNA Biology
- Ph.D. in Tumor Cell Biology, The Catholic University, South Korea
- Specialty: RNA variation and functional study in tumor immunity
- SCI paper: 11, Patent: 5

Leader Sang Yean Kim
- Lab of Cancer RNA Biology
- Ph.D. in Tumor Cell Biology, The Catholic University, South Korea
- Specialty: cancer RNA variation and functional study
- SCI paper: 7, Patent: 3

Leader Jung Hwan Yoon
- Research Lecturer, The Department of Pathology, The Catholic University, South Korea
- Ph.D. in Tumor Cell Biology, The Catholic University, South Korea
- Specialty: Carcinogenesis and progression mechanism study in gastric cancer
- SCI paper: 50, Patent: 13
Collaborator
Domestic
Overseas
Contact us
Headquarter
-
Address
#5104, Catholic Omnibus Park Building A, The Catholic Univ. of Korea Banpo-daero 222, Secho-gu, Seoul (06591)
-
TEL
02-2258-7308
-
FAX
02-537-6586
Research center
-
Address
2F, 47-3, Banpo-daero 39-gil, Seocho-gu, Seoul (06579)
-
TEL
02-595-2812
-
FAX
02-595-2810